These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3156664)

  • 1. Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
    Hu KN; Kim A; Khan AS; Soroff H; Gonder M
    Cancer; 1985 Apr; 55(8):1654-8. PubMed ID: 3156664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
    Mobley WC; Loening SA; Narayana AS; Culp DA
    Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
    Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
    J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
    Heney NM
    Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
    Seraphim LA; Perrapato SD; Slocum HK; Rustum YM; Huben RP
    J Urol; 1991 Mar; 145(3):613-7. PubMed ID: 1900087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
    Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ
    J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa.
    Issell BF; Prout GR; Soloway MS; Cummings KB; Brannen G; Veenema R; Flanagan M; Block NL; Summers JL; Levin EA
    Cancer; 1984 Mar; 53(5):1025-8. PubMed ID: 6420039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
    Hardeman SW; Perry A; Soloway MS
    J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical chemotherapy for superficial bladder cancer.
    Koontz WW
    Urology; 1984 Apr; 23(4 Suppl):79-81. PubMed ID: 6424298
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
    Soloway MS
    J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic treatment for superficial bladder cancer following transurethral resection.
    Hirao Y; Okajima E; Ohara S; Ozono S; Hiramatsu T; Yoshida K; Yamada K; Aoyama H; Hashimoto M; Watanabe S
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S85-90. PubMed ID: 3117402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for bladder cancer.
    Whitmore WF
    J Urol; 1985 Dec; 134(6):1181-2. PubMed ID: 3932688
    [No Abstract]   [Full Text] [Related]  

  • 16. [Intravesical chemotherapy for superficial bladder tumors].
    Ohmori H
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1557-62. PubMed ID: 6206797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical chemotherapy for superficial carcinoma of the bladder.
    Foo KT; Tan EC; Tung KH; Tock EP
    Singapore Med J; 1991 Dec; 32(6):420-2. PubMed ID: 1788600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
    van der Meijden AP; DeBruyne FM
    Urology; 1988 Mar; 31(3 Suppl):26-9. PubMed ID: 3126592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer.
    Cant JD; Murphy WM; Soloway MS
    Cancer; 1986 Jun; 57(11):2119-22. PubMed ID: 3084057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.